Form 4: Olema Pharma Director Sells All Shares After Option Exercise

Olema Pharmaceuticals Director Ian T. Clark exercised stock options and immediately sold all resulting shares on December 19, 2025.

Summary

• Ian T. Clark, a Director of Olema Pharmaceuticals, Inc. (OLMA), reported multiple transactions on December 19, 2025.
• Clark exercised stock options to acquire a total of 264,800 shares of common stock.
• The exercise prices for these options ranged from $3.61 to $7.84 per share.
• Immediately following the option exercises, Clark sold all 264,800 shares of common stock.
• The sales were executed at weighted average prices ranging from $28.83 to $30.48 per share.
• Following these transactions, Clark's direct beneficial ownership of Olema Pharmaceuticals common stock is 0 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a director selling all their shares and reducing their direct beneficial ownership to zero, which can signal a lack of confidence in the company's future, despite the transactions being profitable for the individual.

Positives

• The exercise of stock options at significantly lower prices ($3.61 $7.84) compared to the market sale prices ($28.83 $30.48) indicates a substantial profit for the reporting person.

Negatives

• A director selling all their beneficially owned shares, reducing their direct ownership to zero, could be perceived negatively by the market as a lack of confidence in the company's future prospects.
• The significant volume of shares sold (264,800 shares) represents a notable insider divestment.

Future Outlook

NA

Industry Context

This transaction is an individual insider trading event and does not directly reflect broader industry trends, though significant insider selling can sometimes be a signal within the biotech/pharma sector if it's widespread.

Stakeholder Impact

• Shareholders: May interpret the complete divestment by a director as a negative signal, potentially impacting investor confidence and share price.
• Employees: No direct impact mentioned, but a perceived lack of confidence from a director could subtly affect morale.

Next Steps

• The remaining 12,080 derivative securities (stock options) held by the reporting person will continue to vest according to the schedule outlined in footnote 5.

Key Dates

Recommendation

The complete divestment of direct beneficial ownership by a director, even if it's an exercise-and-sell of options, typically signals a lack of long-term conviction in the company's stock performance. While the director profited from the options, the zero remaining direct ownership suggests they see limited upside or potential downside, which could lead a seasoned investor to consider selling or reducing their position.

Keywords

Olema Pharmaceuticals, OLMA, Insider Trading, Form 4, Stock Options, Director Sales, Equity Transactions, Beneficial Ownership